CASRAI Dictionary

Tag: nih research misconduct

  • Research Misconduct Federal Funding: Grant Risk

    When an allegation of research misconduct is opened against a federally funded project, the grant does not simply continue as normal. The funding agency can defer draw-downs, restrict how funds are spent, or suspend the award outright, while the awardee institution — not the agency — conducts the inquiry and investigation under research misconduct federal funding rules that require prompt notification, safeguarding of funds, and, if misconduct is confirmed, cost recovery or debarment.

    Research misconduct is fabrication, falsification, or plagiarism in proposing, performing, or reviewing federally funded research, or in reporting its results — a definition set by the Office of Science and Technology Policy’s 2000 Federal Policy on Research Misconduct (65 Fed. Reg. 76,260) and applied by every major federal research funder.

    What Is Research Misconduct Under Federal Policy?

    Federal research misconduct policy applies a single, government-wide standard: fabrication, falsification, or plagiarism (FFP) committed in proposing, performing, or reviewing federally funded research, or in reporting its results. Under the OSTP Federal Policy on Research Misconduct, a finding requires proof that the conduct represents “a significant departure from accepted practices,” was committed “intentionally, or knowingly, or recklessly,” and is established “by a preponderance of the evidence” — a civil, not criminal, standard.

    Honest error and legitimate differences of scientific opinion are explicitly excluded. The policy also does not cover authorship disputes, harassment, or general grant-management violations, which fall under separate institutional or agency processes.

    • Fabrication — making up data or results and recording or reporting them.
    • Falsification — manipulating materials, equipment, or data so the research record is not accurately represented.
    • Plagiarism — appropriating another person’s ideas, processes, results, or words without credit.

    What Happens to Grant Funds During an Investigation?

    A grant under a misconduct inquiry does not automatically stop, but the funding agency retains authority to take interim administrative actions to protect federal funds while the institution investigates. These typically include deferring decisions on continued funding, restricting the purposes for which existing funds may be spent, requiring special award certifications, or — where the risk is severe — suspending the active award pending outcome.

    Responsibility for the investigation sits primarily with the recipient institution, not the funder. Under Public Health Service (PHS) rules governing NIH-funded research (42 CFR Part 93), and the parallel National Science Foundation framework (45 CFR Part 689), the institution runs its own inquiry and investigation while the agency monitors, can intervene, and controls the purse strings throughout.

    Investigation stage Typical fund status Who acts
    Institutional assessment / inquiry Funds usually continue; agency may be informed Research Integrity Officer (RIO)
    Formal investigation opened Agency may defer, restrict, or condition funding Institution investigates; ORI or NSF OIG notified
    Investigation concluded, misconduct found Suspension, termination, or debarment possible Agency Inspector General / Deciding Official

    Who Must Notify the Funding Agency, and When?

    Every institution receiving PHS or NSF funding is required, as a condition of its funding assurance, to notify the relevant federal office once a formal investigation is opened. For NIH and other Public Health Service awards, that notice goes to HHS’s Office of Research Integrity (ORI); for NSF awards, it goes to the NSF Office of Inspector General (OIG).

    Notification cannot wait for the case to close. If the institution determines during an inquiry or investigation that public health or safety is at risk, that federal interests or resources are threatened, that research activities should be suspended, or that there is a reasonable indication of a possible civil or criminal law violation, it must notify the agency immediately — not at the standard reporting milestones.

    • Immediate notice — health/safety risk, threat to federal resources, or suspected civil/criminal violation.
    • Formal notice at investigation opening — required under the institution’s PHS or NSF assurance.
    • Closing report — the full institutional record, transmitted to ORI or NSF OIG after a final misconduct determination and any institutional appeal.

    What Are the Consequences If Misconduct Is Confirmed?

    If an investigation substantiates research misconduct, the funding agency can impose administrative sanctions independent of, and in addition to, any action the institution itself takes. Under ORI’s guidance on federal policy, “the Federal Government can debar researchers who commit misconduct from receiving Federal funds for a specified period of time,” and institutions commonly pursue their own parallel actions such as termination of employment or mandated supervision of future work.

    Available federal administrative actions include:

    • Correction of the published research record and retraction of affected papers.
    • Letters of reprimand or special certification requirements on future awards.
    • Suspension or termination of the active award, with recovery of misspent federal funds.
    • Suspension or debarment from federal funding, published on the General Services Administration’s SAM.gov exclusions list.
    • Referral to the Department of Justice where civil or criminal fraud is suspected.

    Cost recovery is a distinct lever from debarment: an institution can be required to repay funds tied to fabricated or falsified data even where an individual researcher, not the institution, is the primary respondent.

    How Does the 2024 Final Rule Change the Process?

    The compliance landscape shifted materially with HHS’s Final Rule updating 42 CFR Part 93, published in the Federal Register on 17 September 2024 and formally titled “Public Health Service Policies on Research Misconduct.” The rule took effect 1 January 2025, but institutions were required to apply its new procedural requirements to any allegation received on or after 1 January 2026, with updated institutional policies due to ORI no later than the annual report covering 2025 (filed by 30 April 2026).

    The Final Rule extends two of the timelines research administrators rely on most:

    • Inquiry period: extended from 60 days under the 2005 regulation to 90 days.
    • Investigation period: extended from 120 days under the 2005 regulation to 180 days.

    It also formalises a new pre-inquiry “institutional assessment” stage (§93.306), in which the Research Integrity Officer must document whether an allegation falls within the misconduct definition and PHS jurisdiction before an inquiry is opened — with no fixed time limit for this new stage. The rule further clarifies confidentiality obligations, allowing institutions to disclose respondent identities to journals, co-authors, and collaborating institutions where there is a legitimate need to know, and expands provisions covering multiple respondents and multi-institution proceedings.

    Frequently Asked Questions

    Does the Funding Agency Investigate Misconduct Directly, or Does the Institution?

    The institution conducts the initial inquiry and investigation, not the federal funding agency. Agencies such as ORI or the NSF OIG monitor the case, can intervene if the institution is unable or unwilling to act, and retain authority over the grant throughout.

    What Standard of Proof Applies to a Misconduct Finding?

    A finding requires proof “by a preponderance of the evidence” — more likely than not — not the criminal “beyond a reasonable doubt” standard. The conduct must also be shown to have been committed intentionally, knowingly, or recklessly, and to represent a significant departure from accepted research practice.

    What Is the First Phase of a Research Misconduct Response?

    The process begins with an institutional assessment or inquiry — a preliminary review to decide whether an allegation has enough substance to warrant a full investigation. Under the 2024 Final Rule, this assessment stage is now formally documented before any inquiry clock starts running.

    To Whom Does the Federal Research Misconduct Policy Apply?

    The policy applies to anyone proposing, performing, or reviewing federally funded research — including applicants, grant recipients, subrecipients, project participants, and peer reviewers — at any institution receiving Public Health Service or comparable federal research funding.

    Implications for Research Administrators

    The practical exposure is threefold: a live award can be frozen or restricted mid-project, cost recovery can claw back funds already spent, and delayed or incomplete notification to the funder is a compliance failure in its own right, separate from the underlying allegation. Research integrity offices should treat the 2026 compliance deadline as a trigger to audit their policies against the extended 90/180-day timelines and the new institutional-assessment stage — a policy still reflecting the 2005 regulation’s 60/120-day clock no longer matches what ORI expects in an institutional record.

    The Final Rule’s added reporting elements — sequestration inventories, interview transcripts, and multi-institution coordination — point toward longer, more paperwork-intensive proceedings even as deadlines extend. For anyone administering federally funded research, what happens to the grant while a case runs is as important as the underlying definition of misconduct itself.

  • ORI Research Misconduct Case Summaries Database: What It Publishes and Removes

    The ORI Case Summaries database is the U.S. Office of Research Integrity’s public register of confirmed research misconduct findings involving Public Health Service-funded research. Each entry names the respondent, describes the fabrication, falsification, or plagiarism found, and lists the administrative sanctions imposed — but, unlike a permanent archive, a case is removed from the live list once its sanction period expires.

    The ORI research misconduct case summaries register is the closest thing the U.S. federal research-integrity system has to a public “misconduct docket.” For research administrators, publishers, and compliance officers, understanding exactly what it discloses — and, just as importantly, what it stops disclosing over time — is essential to using it correctly as a due-diligence tool.

    The Office of Research Integrity (ORI) is the HHS component that oversees research integrity for Public Health Service-supported research, a remit that in practice covers the great majority of federally funded biomedical science, including nearly all NIH-funded work.

    What is the ORI Case Summaries database?

    The ORI Case Summaries database is a page maintained at ori.hhs.gov listing individuals against whom ORI has made a formal finding of research misconduct and imposed an administrative action. It is not a docket of allegations or open investigations — a case only appears once an inquiry and full investigation have concluded and ORI has accepted the finding.

    Research misconduct itself is narrowly defined under 42 CFR Part 93 as fabrication, falsification, or plagiarism (FFP) in proposing, performing, or reviewing research, or in reporting research results. Disputes about interpretation, authorship credit, or research design are explicitly excluded from this definition, which is why the register is narrower than the broader universe of retracted papers.

    ORI itself, established in 1992 within HHS, does not conduct most investigations directly. Institutions receiving PHS funds are required to investigate allegations under their own procedures and report outcomes to ORI, which then reviews the institutional finding before a case summary is published.

    What information is disclosed in each case summary?

    Each published case summary follows a broadly consistent disclosure pattern, even though length and detail vary case by case. This consistency is what makes the register usable as a structured compliance-checking resource rather than a set of one-off press notices.

    • Respondent identity — the named individual found to have committed misconduct, plus their institution at the time of the conduct.
    • Nature of the misconduct — which category of fabrication, falsification, or plagiarism was found, and in what context (grant application, published paper, data submitted to PHS).
    • Affected research — the specific publications, images, datasets, or grant materials implicated, often naming the journal or funding mechanism.
    • Administrative actions — the sanctions ORI imposed, which can include debarment from receiving federal funds, exclusion from PHS advisory or peer-review service, and supervision or certification requirements for any future PHS-supported research.
    • Corrective steps — where applicable, a note that the respondent must request retraction or correction of the affected literature.

    What the summaries generally do not disclose is the full institutional investigation report, interview transcripts, or the raw evidentiary record — those remain with the institution and are only obtainable, if at all, through a separate public-records request.

    How long do case summaries stay public?

    This is the detail most guidance on the ORI register omits, and it materially changes how the database should be used. ORI’s own case summary page states that the list only includes respondents who currently have an administrative action in effect — once a debarment, supervision period, or certification requirement expires, the case summary is removed from the live online list.

    In practice, this means the ori.hhs.gov register functions as an active-sanctions list, not a permanent misconduct archive. A researcher sanctioned for three years in 2020 will typically no longer appear on the current page by 2026, even though the underlying finding was never reversed. Older findings persist instead in ORI’s historical newsletters and in contemporaneous Federal Register and NIH Guide for Grants and Contracts notices, which are not removed once published.

    For anyone conducting due diligence — a journal editor vetting a submission, a hiring institution, or a funder — checking the live case summaries page alone is not sufficient to establish that a researcher has a clean misconduct history; the historical notice archive must also be checked.

    How does it compare with other misconduct registers?

    Research administrators often conflate the ORI register with other misconduct- and retraction-tracking resources. They serve different purposes and, critically, have very different persistence rules.

    Register Scope Named respondent? Persistence
    ORI Case Summaries (ori.hhs.gov) PHS/NIH-funded research with a confirmed misconduct finding and an active sanction Yes Removed once the sanction period expires
    ORI historical notices (NIH Guide / Federal Register) Same findings, at time of original publication Yes Permanent archival record
    Retraction Watch Database Retracted or corrected papers from any funder, any cause (misconduct, error, or dispute) Sometimes, via linked retraction notice Permanent
    Institutional investigation reports Single institution, single case Varies by institution’s public-records policy Retained per institutional records policy, rarely public by default

    The practical takeaway: the ORI register and the Retraction Watch Database answer different questions. ORI tells you whether someone is currently under federal sanction; Retraction Watch tells you whether a specific paper has been retracted or corrected, regardless of whether any individual was ever sanctioned by ORI.

    Common questions about ORI case summaries

    Are researchers named in ORI case summaries?

    Yes. Once ORI has finalised a finding of research misconduct and imposed an administrative action, the respondent’s name and affiliated institution are published in the case summary. This differs from the confidentiality that generally applies while an inquiry or investigation is still open and unresolved.

    What happens to a case summary once the sanction ends?

    The entry is removed from the live online list at ori.hhs.gov once the administrative action — debarment, supervision, or certification requirement — expires. The finding itself is not reversed; it persists instead in ORI’s historical newsletters and Federal Register notices, which remain permanently accessible.

    Where else are ORI misconduct findings published besides the website?

    Beyond the case summaries page, ORI findings have historically been announced through the NIH Guide for Grants and Contracts, the ORI Newsletter, and Federal Register notices. These channels provide an archival record that outlasts the rolling, sanctions-only website list.

    What this means for research administrators and publishers

    For institutional research integrity officers, the practical implication is clear: the ORI Case Summaries page is a screening tool for active sanctions, not a comprehensive misconduct history check. A clean search result today does not confirm a researcher has never been found to have committed misconduct — only that no sanction is currently in force.

    A 2024 modernisation of the underlying regulations at 42 CFR Part 93, with a 1 January 2026 effective date, updated investigation and reporting procedures between institutions and ORI, but did not change this fundamental “currently sanctioned” design of the public case summary list. Institutions building author-vetting, hiring, or peer-reviewer-screening workflows should pair a live ORI search with a check of ORI’s historical notice archive and, where the concern involves a specific publication, the Retraction Watch Database.

    As research-integrity oversight continues to modernise, the case for a permanent, jointly maintained misconduct record — rather than a rolling active-sanctions list — is likely to grow, particularly as funders and publishers increasingly expect due diligence to extend beyond an individual’s current sanction status.

    For related definitions and standards context, see the CASRAI Dictionary and the broader research administration resource hub.

  • ORI Research Misconduct Policy: 2026 Annual Assurance Renewal Explained

    The ORI research misconduct policy that governs Public Health Service (PHS)-funded research changed materially for 2026, and the annual paperwork cycle that keeps an institution’s assurance active has not paused to accommodate the transition. Every institution that holds a PHS assurance under 42 CFR Part 93 — whether or not it has an open case — must file its Annual Report on Possible Research Misconduct between 1 January and 30 April 2026, and for the first time that filing sits alongside a revised regulatory framework institutions are expected to have already adopted.

    This is a mechanics piece, not a restatement of the Final Rule’s substance. It sets out exactly what the U.S. Department of Health and Human Services’ Office of Research Integrity (ORI) expects institutions to submit for the 2026 assurance renewal cycle, which form to use, and where the transition from the 2005 regulation creates procedural traps for research integrity officers (RIOs) and sponsored-programs staff.

    What changed: the Final Rule and the 2026 effective date

    ORI’s revised Public Health Service Policies on Research Misconduct — published in the Federal Register on 17 September 2024 and codified at 42 CFR Part 93 — took effect on 1 January 2026. It is the first substantive rewrite of the misconduct regulation since 2005, and it introduces more than twenty-five newly defined terms, including “institutional record,” “administrative record,” “intentionally,” and “recklessly,” aimed at tightening consistency across institutional proceedings.

    The core three-part definition of research misconduct is unchanged: fabrication, falsification, or plagiarism (FFP) that represents a significant departure from accepted practices of the relevant research community, committed intentionally, knowingly, or recklessly, and proven by a preponderance of the evidence. What has changed is procedural detail — respondent comment rights on draft investigation reports, record-retention protocols, and interim-action notification triggers are now spelled out in greater depth.

    Critically, the Final Rule is not retroactive. Allegations received before 1 January 2026 continue to be handled under the 2005 version of Part 93 unless the institution and the respondent agree in writing to proceed under the new rule. Institutions running dual-track proceedings across the transition need to document, case by case, which regulatory version applies.

    Who must file an assurance renewal, and via which form

    Any institution that receives PHS-supported research funds — including awards from NIH, CDC, FDA, HRSA, and other PHS agencies — must maintain an active research misconduct assurance with ORI. Once an assurance is established, the institution is obligated to file annually, regardless of whether it received any misconduct allegations that year.

    • Form: Annual Report on Possible Research Misconduct, Form PHS-6349, submitted through ORI’s online Annual Report system (ARPRM).
    • Filing window: 1 January through 30 April each calendar year, covering the prior calendar year’s activity.
    • 2026 deadline: 30 April 2026, covering the reporting period 1 January–31 December 2025.
    • No-activity institutions: institutions with no PHS-supported research or no allegations in the reporting period may still owe a report; small or inactive institutions should confirm with ORI’s Assurance Program whether a Small Institution or no-activity statement applies to their circumstances.
    • Access: ORI’s Annual Report system now requires two-factor authentication (2FA) — institutions should confirm their registered email with the Assurance Program ([email protected]) well before the deadline to avoid last-minute access issues.

    The 2026 assurance renewal checklist

    Beyond the Form PHS-6349 filing itself, 2026 is unusual because institutions are also expected to have brought their internal policies and procedures into alignment with the new 42 CFR Part 93 requirements. ORI published a Sample Policies and Procedures document in June 2025 specifically to help research integrity officers, compliance staff, and institutional counsel update their templates ahead of the 1 January 2026 effective date.

    Item 2005 rule (pre-2026 cases) 2026 Final Rule
    Effective date 16 June 2005 1 January 2026
    Defined terms in 42 CFR Part 93 Baseline set 25+ additional defined terms
    Applies to allegations received Before 1 Jan 2026 (default) From 1 Jan 2026 onward, or earlier by written agreement
    Annual Report on Possible Research Misconduct Form PHS-6349, Jan–Apr window Unchanged: Form PHS-6349, Jan–Apr window
    Institutional policy alignment N/A Sample Policies and Procedures released June 2025

    Institutions preparing their 2026 renewal should treat the filing as a two-part exercise: (1) submit Form PHS-6349 through ARPRM by 30 April 2026 for the 2025 reporting year, and (2) confirm that the policies and procedures referenced in that assurance actually reflect the post-1-January-2026 regulatory text, not the 2005 language many institutional websites still carry. ORI’s own research administration compliance guidance and case-summary archive remain useful references for RIOs benchmarking their inquiry and investigation timelines against the 60-day inquiry and 120-day investigation targets that persist in the revised rule.

    Frequently asked questions

    What is the deadline for the ORI 2026 annual assurance renewal?

    Institutions holding a PHS research misconduct assurance must file the Annual Report on Possible Research Misconduct (Form PHS-6349) between 1 January and 30 April 2026, covering research misconduct activity from the 2025 calendar year, via ORI’s online ARPRM system.

    Which institutions must maintain an ORI research misconduct assurance?

    Any institution receiving Public Health Service-supported research funds — from NIH, CDC, FDA, or other PHS agencies — must hold an active assurance under 42 CFR Part 93 and file annually, even in years with no reported allegations.

    Does the new ORI Final Rule apply retroactively to open cases?

    No. Allegations received before 1 January 2026 are handled under the 2005 version of 42 CFR Part 93 by default, unless the institution and respondent agree in writing to proceed under the revised rule instead.

    What form and system do institutions use to submit their annual report?

    Institutions submit Form PHS-6349 through ORI’s Annual Report on Possible Research Misconduct system (ARPRM), which now requires two-factor authentication tied to the institution’s registered email address.

    Implications for research administrators

    The overlap between the Final Rule’s 1 January 2026 effective date and the routine 30 April annual report deadline compresses an already tight compliance calendar. Research integrity officers now need to reconcile three separate obligations in the same window: filing the standard annual report, confirming that institutional policies match the revised regulatory text, and correctly classifying any pending allegation as either a 2005-rule case or a 2026-rule case for procedural purposes.

    ORI’s most recent published Annual Report, covering 2024 activity, recorded 713 allegations of possible research misconduct and 117 new cases opened that year, with 38 cases carried over from prior years — a caseload that gives some sense of scale for institutions weighing how much internal capacity to dedicate to inquiry and investigation infrastructure under the tightened procedural clock.

    • Audit institutional policy language against ORI’s June 2025 Sample Policies and Procedures document before certifying compliance in the 2026 assurance filing.
    • Tag open cases by intake date to determine which regulatory version (2005 or 2026) governs each proceeding.
    • Confirm ARPRM account access and two-factor authentication setup well ahead of the 30 April deadline — do not wait for filing week.
    • Brief institutional review boards and legal counsel on the expanded defined terms, particularly “recklessly” and “intentionally,” which affect how misconduct findings are documented.

    Looking ahead

    The 2026 cycle is likely to be the messiest transition year institutions face under 42 CFR Part 93 for some time: two regulatory regimes running in parallel, a compressed policy-update timeline, and an unchanged annual filing deadline that does not care which rule applies to a given case. Institutions that treat the 30 April 2026 Form PHS-6349 submission purely as a data return — rather than as an opportunity to verify their underlying policies actually match the current regulation — risk finding gaps only when ORI reviews a proceeding. Research administrators tracking related standards work, including contributor-role and authorship frameworks referenced in misconduct findings, can cross-reference CASRAI’s CRediT contributor role and authorship resources when documenting responsibility in a research record.